Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

Searched for: Liver Cancer. 7 results shown below.

A Phase I Study of Temozolomide, oral Irinotecan and Vincristine for Children with Refractory Solid Tumors
Principal Investigator: Julie Park, MD
Study Number: COG ADVL0414
Phase: I

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

[Complete title: A Phase III Clinical Trial of Intra-arterial TheraSphere in the Treatment of Patient with Unresectable Hepatocellular Carcinoma (HCC)]
Principal Investigator: William Harris
Study Number: 20111617
Phase: III

Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy

[Complete title: POLARIS2009-001: A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy]
Principal Investigator: William Harris
Study Number: 20120106
Phase: III

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy

[Complete title: A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy]
Principal Investigator: William Harris
Study Number: 20122073
Phase: III

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)

[Complete title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib]
Principal Investigator: William Harris
Study Number: 20130857
Phase: III

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

[Complete title: A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma]
Principal Investigator: William Harris
Study Number: 20131240
Phase: III

Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer

[Complete title: A Phase 1 Study of ADI-PEG 20 Plus Sorafenib in Subjects WithAdvanced Hepatocellular Carcinoma (HCC)]
Principal Investigator: William Harris
Study Number: 20142070
Phase: I

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials